On the heels of the WINTHER study, the consortium has planned a new trial called MERCURY, and will launch a blood and tissue repository.
The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
Exome sequencing on tumors from metastatic, castration-resistant prostate cancer cases responding to immunotherapy led to homologous recombination defects.
A phase 1 study from MD Anderson saw a modest increase in overall and progression-free survival in cancer patients molecularly matched to treatment.
The Hartwig Medical Foundation currently sequences about 7.5 percent of all metastatic cancer biopsies in the Netherlands, processing 250 to 300 samples per month.
A Phase III randomized trial uncovered enhanced carboplatin response in advanced triple-negative breast cancer patients with germline mutations affecting BRCA1/2.
The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.
The transcription factor FOXM1 marked meningioma cases with poorer outcomes and enhanced cell proliferation, based on integrated exome, expression, and epigenetic profiles.
Two new analyses have identified driver genes, altered pathways, mutational signatures, and other molecular features across two dozen cancer subtypes.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
Cancer researcher Alan Rabson has died at 92, the New York Times reports.
As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.
In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.
The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.